Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery

NACompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

September 7, 2015

Primary Completion Date

April 2, 2016

Study Completion Date

April 2, 2016

Conditions
Abdominal Mass
Interventions
DRUG

Ondansetron

Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.

DRUG

Ramosetron

Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.

All Listed Sponsors
lead

Yonsei University

OTHER

NCT03017222 - Therapeutic Efficacy of Ramosetron for Treatment of Established PONV After Laparoscopic Surgery | Biotech Hunter | Biotech Hunter